2021
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart 2021, 8: e001849. PMID: 34952868, PMCID: PMC8710909, DOI: 10.1136/openhrt-2021-001849.Peer-Reviewed Original ResearchConceptsCardiovascular adverse eventsAdverse Event Reporting SystemCombination therapyAntimicrotubular agentsVinca alkaloidsAdverse eventsDrug Administration Adverse Event Reporting SystemRoutine cardiovascular assessmentCardiovascular safety profilePolytomous logistic regressionEvent Reporting SystemAgent therapyCombination chemotherapyHeart failureRegistry experienceSafety profileCardiovascular assessmentHigh burdenInhibitor combinationsChemotherapeutic agentsTaxanesTherapyLogistic regressionMonotherapyReporting system
2020
Cardiovascular disease in women: insights from magnetic resonance imaging
Bucciarelli-Ducci C, Ostenfeld E, Baldassarre LA, Ferreira VM, Frank L, Kallianos K, Raman SV, Srichai MB, McAlindon E, Mavrogeni S, Ntusi NAB, Schulz-Menger J, Valente AM, Ordovas KG. Cardiovascular disease in women: insights from magnetic resonance imaging. Journal Of Cardiovascular Magnetic Resonance 2020, 22: 71. PMID: 32981527, PMCID: PMC7520984, DOI: 10.1186/s12968-020-00666-4.Peer-Reviewed Original ResearchConceptsCardiovascular magnetic resonanceCardiovascular diseaseValue of CMRRole of CMRPulmonary arterial hypertensionUnique diagnostic challengeConnective tissue disordersMagnetic resonance imagingArterial hypertensionPeripartum cardiomyopathyUnderrecognized conditionCardiovascular differencesPrognostic roleFemale patientsPatient populationDiagnostic challengeTissue disordersCardiovascular disordersResonance imagingClinical mismanagementDiseaseImaging modalitiesWomenSex differencesFurther investigation